الولايات المتحدة · منصات وبيانات · MarketBeat
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

ملخص مفصل
Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027. At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagsh
يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)




